Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
JAK2 and hepatocellular carcinoma are reported together in 6 articles.
Gene
JAK2
- HGNC
- HGNC:6192
83articles
83mentions
1variants with confirmed gene link
Most co-reported phenotypes (articles)
leukemia 10breast cancer 7diabetes mellitus 7hepatocellular carcinoma 6colorectal cancer 5lung cancer 3multiple myeloma 3stroke 3
Reported variants (articles · ClinVar status)
Phenotype
Hepatocellular carcinoma
417articles
417mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
6 records shown · first 60Leonurine ameliorates the STAT3 pathway through the upregulation of SHP-1 to retard the growth of hepatocellular carcinoma cells.
PMID 38048857 | DOI 10.1016/j.cellsig.2023.111003 · Cellular signalling · 2024 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | JAK2 | “Leo was also found to impart STAT3 inhibition by mitigating the activation of upstream kinases such as JAK1, JAK2, and Src both in constitutive and IL-6 inducible systems.” | 0.98 | hgnc_dict_v1 |
| phenotype | hepatocellular carcinoma | “Leonurine ameliorates the STAT3 pathway through the upregulation of SHP-1 to retard the growth of hepatocellular carcinoma cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | STAT3 | “Leonurine ameliorates the STAT3 pathway through the upregulation of SHP-1 to retard the growth of hepatocellular carcinoma cells.” | 0.98 | hgnc_dict_v1 |
| gene | JAK1 | “Leo was also found to impart STAT3 inhibition by mitigating the activation of upstream kinases such as JAK1, JAK2, and Src both in constitutive and IL-6 inducible systems.” | 0.98 | hgnc_dict_v1 |
Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway.
PMID 34771643 | PMCID PMC8582575 | DOI 10.3390/cancers13215479 · Cancers · 2021 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | JAK2 | “Tris DBA decreased cell viability, increased apoptosis, and inhibited IL-6 induced/constitutive activation of STAT3, JAK1, JAK2, and Src in HCC and MM cells.” | 0.98 | hgnc_dict_v1 |
| phenotype | hepatocellular carcinoma | “Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | STAT3 | “Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway.” | 0.98 | hgnc_dict_v1 |
| gene | JAK1 | “Tris DBA decreased cell viability, increased apoptosis, and inhibited IL-6 induced/constitutive activation of STAT3, JAK1, JAK2, and Src in HCC and MM cells.” | 0.98 | hgnc_dict_v1 |
Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma.
PMID 34514729 | DOI 10.1002/iub.2555 · IUBMB life · 2021 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | JAK2 | “Crocetin suppressed the activity of upstream kinases such as Src, JAK1, and JAK2.” | 0.98 | hgnc_dict_v1 |
| phenotype | hepatocellular carcinoma | “Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | STAT3 | “Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma.” | 0.98 | hgnc_dict_v1 |
| gene | JAK1 | “Crocetin suppressed the activity of upstream kinases such as Src, JAK1, and JAK2.” | 0.98 | hgnc_dict_v1 |
3-Formylchromone Counteracts STAT3 Signaling Pathway by Elevating SHP-2 Expression in Hepatocellular Carcinoma.
PMID 35053027 | PMCID PMC8773260 | DOI 10.3390/biology11010029 · Biology · 2021 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | JAK2 | “3FC downregulated the constitutive phosphorylation of STAT3 and non-receptor tyrosine kinases such as JAK1 and JAK2.” | 0.98 | hgnc_dict_v1 |
| phenotype | hepatocellular carcinoma | “3-Formylchromone Counteracts STAT3 Signaling Pathway by Elevating SHP-2 Expression in Hepatocellular Carcinoma.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | STAT3 | “3-Formylchromone Counteracts STAT3 Signaling Pathway by Elevating SHP-2 Expression in Hepatocellular Carcinoma.” | 0.98 | hgnc_dict_v1 |
| gene | JAK1 | “3FC downregulated the constitutive phosphorylation of STAT3 and non-receptor tyrosine kinases such as JAK1 and JAK2.” | 0.98 | hgnc_dict_v1 |
Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway.
PMID 32445654 | DOI 10.1016/j.biochi.2020.05.006 · Biochimie · 2020 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | JAK2 | “Vitexin effectively inhibited sustained activation of JAK1, JAK2, Src, and STAT3 in HCC cells.” | 0.98 | hgnc_dict_v1 |
| phenotype | hepatocellular carcinoma | “Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | STAT3 | “Vitexin abrogates invasion and survival of hepatocellular carcinoma cells through targeting STAT3 signaling pathway.” | 0.98 | hgnc_dict_v1 |
| gene | JAK1 | “Vitexin effectively inhibited sustained activation of JAK1, JAK2, Src, and STAT3 in HCC cells.” | 0.98 | hgnc_dict_v1 |
Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
PMID 31619257 | PMCID PMC6794763 | DOI 10.1186/s12964-019-0430-7 · Cell communication and signaling : CCS · 2019 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | JAK2 | “CONCLUSION: Our data suggest that PH inhibits STAT3 activity in Sor-sensitive and -resistant HCCs via SHP-1-mediated inhibition of STAT3 and AKT/mTOR/JAK2/VEGFR2 pathway.” | 0.98 | hgnc_dict_v1 |
| phenotype | hepatocellular carcinoma | “Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | STAT3 | “Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.” | 0.98 | hgnc_dict_v1 |
| variant | D61A | “Further, we used purified SHP-1 proteins or HCC cells expressing deletion N-SH2 domain or D61A point mutants to study the PH efficacy on SHP-1.” | 0.82 | literature_variant_regex_v2 |